TITLE:
Alternate Day Buprenorphine Administration, Phase IX - 14

CONDITION:
Opioid-Related Disorders

INTERVENTION:
Buprenorphine

SUMMARY:

      The purpose of this study is to determine if four times a subjects' daily maintenance dose
      will hold for 120 hours without changes in agonist and antagonist effects.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 22 Years to 51 Years
Criteria:

        Please contact site for information.
      
